Cargando…
Response to Ovarian Stimulation for Urgent Fertility Preservation before Gonadotoxic Treatment in BRCA-Pathogenic-Variant-Positive Breast Cancer Patients
SIMPLE SUMMARY: BRCA 1/2 pathogenic variants increase the risk of developing early and aggressive breast cancers. For these patients, fertility potential can be directly affected by oncologic treatments. In order to improve their chances of conception after the completion of cancer treatments, ferti...
Autores principales: | El Moujahed, Lina, Philis, Robin, Grynberg, Michael, Laot, Lucie, Mur, Pauline, Amsellem, Noemi, Mayeur, Anne, Benoit, Alexandra, Rakrouki, Sophia, Sifer, Christophe, Peigné, Maeliss, Sonigo, Charlotte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913552/ https://www.ncbi.nlm.nih.gov/pubmed/36765851 http://dx.doi.org/10.3390/cancers15030895 |
Ejemplares similares
-
Should Preimplantation Genetic Testing (PGT) Systematically Be Proposed to BRCA Pathogenic Variant Carriers?
por: Laot, Lucie, et al.
Publicado: (2022) -
Comparison of GnRH agonist and hCG for priming in vitro maturation cycles in cancer patients undergoing urgent fertility preservation
por: El Hachem, Hady, et al.
Publicado: (2018) -
Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger?
por: Lalami, Imane, et al.
Publicado: (2022) -
Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients
por: Sonigo, Charlotte, et al.
Publicado: (2019) -
Double-in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible
por: Sermondade, Nathalie, et al.
Publicado: (2020)